Investissement

Hillenbrand, Inc. (NYSE:HI) stands out as an attractive investment opportunity amid global trade tensions affecting major economies. Recent tariffs aimed at geopolitical concerns have heightened market volatility, presenting unique opportunities…

Atossa Therapeutics is navigating the challenging biotech landscape with $71 million in cash reserves and no debt. The company currently consumes $21 million per year, which represents 23% of its…